Oncocross Co., Ltd. (KOSDAQ:382150)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,420
-420 (-3.55%)
Jun 27, 2025, 3:30 PM KST
-9.72%
Market Cap 156.16B
Revenue (ttm) 1.07B
Net Income (ttm) -7.26B
Shares Out 11.95M
EPS (ttm) -670.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 192,167
Average Volume 1,194,137
Open 11,840
Previous Close 11,840
Day's Range 11,340 - 11,940
52-Week Range 6,260 - 16,700
Beta n/a
RSI 37.00
Earnings Date Aug 12, 2025

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 382150
Full Company Profile

Financial Performance

In 2024, Oncocross's revenue was 1.07 billion, an increase of 1071.49% compared to the previous year's 91.52 million. Losses were -6.48 billion, 53.8% more than in 2023.

Financial Statements

News

There is no news available yet.